2018-10-18 - Male - 66 Years old
719516
| Adverse reaction report number | 719516 |
| Latest AER version number | 0 |
| Market authorization holder AER number | 627260 |
| Initial received date | 2018-10-18 |
| Latest received date | 2018-10-18 |
| Age | 66 Years |
| Gender | Male |
| Weight | N/A |
| Type of report | Study |
| Reporter type | Pharmacist |
| Source of report | MAH |
| Report outcome | Recovered/resolved |
| Serious report? | Yes |
Reason for seriousness
| Death | |
| Disability | |
| Cogenital anomaly | |
| Life threateting | |
| Hospitalization | |
| Other medically important | Yes |
| Product description | Dosage form | Health product role | Route of administration | Dose | Frequency | Therapy duration | Indication(s) |
|---|---|---|---|---|---|---|---|
| METFORMIN | TABLET | Suspect | Unknown | Product used for unknown indication | |||
| OZEMPIC | SOLUTION SUBCUTANEOUS | Suspect | Subcutaneous | 0.6 Milligram | 1 every 1 Week(s) | Type 2 diabetes mellitus | |
| OZEMPIC | SOLUTION SUBCUTANEOUS | Suspect | Subcutaneous | 1 Milligram | 1 every 1 Week(s) | Type 2 diabetes mellitus | |
| GLICLAZIDE | TABLET | Concomitant | |||||
| JARDIANCE | Concomitant |
| MedDRA version: v.21.1 | |
| Adverse reaction terms | Reaction duration |
|---|---|
| Abdominal discomfort | |
| Vomiting | |